Ionis’ Inotersen NDA Accepted for Priority Review by the FDA

CARLSBAD, Calif., Jan. 8, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA)….Original Article